Loading clinical trials...
Loading clinical trials...
Patients will be enrolled in two stages: * Dose-escalation stage: Approximately 12-24 patients will be enrolled.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Genexine, Inc.
NCT06622434 · Newly Diagnosed Glioblastoma
NCT06816927 · Newly Diagnosed Glioblastoma
NCT05864534 · Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, and more
NCT04474353 · Glioblastoma, Newly Diagnosed Glioblastoma
NCT03345095 · Newly Diagnosed Glioblastoma
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, Seocho
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions